Background: Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the
thyroid gland, accounting for 74–80% of all thyroid cancers. The 1799T> A transversion is an …

Purpose: Oncogenic conversion of BRAF occurs in∼ 44% of papillary thyroid carcinomas
and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is …

Activating mutations of BRAF have been identified in a variety of human cancers, most
notably melanomas and papillary thyroid carcinomas (PTCs). The aim of the present study …

Objective The somatic point mutation in the BRAF gene, which results in a valine-to-
glutamate substitution at residue 600 (BRAFV600E), is an ideal hallmark of papillary thyroid …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and
includes several histological variants. Patients suffering from PTC usually have a good …

BRAF is an oncogene that is commonly mutated in both melanomas and papillary thyroid
carcinomas (PTCs). Usually, mutations in the codons 600 or 601 lead to constitutive activity …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Activating point mutations of the BRAF gene have been recently reported in papillary thyroid
carcinomas. In this study, we analyzed 320 thyroid tumors and six anaplastic carcinoma cell …

Activating mutations in the BRAF kinase gene have recently been reported in human
cancers. The aim of the present study was to determine the frequency of BRAF mutations in …